Immunity & AgeingNeurosciencePeer-reviewed journal article
Terminally differentiated effector memory T cells associate with cognitive and AD-related biomarkers in an aging-based community cohort
Edric D. WinfordiD, Jenny LutshumbaiD, Barbara J. Martin, Donna M. WilcockiD, Gregory A. JichaiD, Barbara S. NikolajczykiD, Ann Marie StoweiD, Adam D. BachstetteriD
Abstract
Background and PurposeThe immune response changes during aging and the progression of Alzheimers disease (AD) and related dementia (ADRD). Terminally differentiated effector memory T cells (called TEMRA) are important during aging and AD due to their cytotoxic phenotype and association with cognitive decline. However, it is not clear if the changes seen in TEMRAs are specific to AD-related cognitive decline specifically or are more generally correlated with cognitive decline. This study aimed to examine whether TEMRAs are associated with cognition and plasma biomarkers of AD, neurodegeneration, and neuroinflammation in a community-based cohort of older adults. MethodsStudy participants from a University of Kentucky Alzheimers Disease Research Center (UK-ADRC) community-based cohort of aging and dementia were used to test our hypothesis. There were 84 participants, 44 women and 40 men. Participants underwent physical examination, neurological examination, medical history, cognitive testing, and blood collection to determine plasma biomarker levels (A{beta}42/A{beta}40 ratio, total tau, Neurofilament Light chain (Nf-L), Glial Fibrillary Acidic Protein (GFAP)) and to isolate peripheral blood mononuclear cells (PBMCs). Flow cytometry was used to analyze PBMCs from study participants for effector and memory T cell populations, including CD4+ and CD8+ central memory T cells (TCM), Naive T cells, effector memory T cells (TEM), and effector memory CD45RA+ T cells (TEMRA) immune cell markers. ResultsCD8+ TEMRAs were positively correlated with Nf-L and GFAP. We found no significant difference in CD8+ TEMRAs based on cognitive scores and no associations between CD8+ TEMRAs and AD-related biomarkers. CD4+ TEMRAs were associated with cognitive impairment on the MMSE. Gender was not associated with TEMRAs, but it did show an association with other T cell populations. ConclusionThese findings suggest that the accumulation of CD8+ TEMRAs may be a response to neuronal injury (Nf-L) and neuroinflammation (GFAP) during aging or the progression of AD and ADRD. As our findings in a community-based cohort were not clinically- defined AD participants but included all ADRDs, this suggests that TEMRAs may be associated with changes in systemic immune T cell subsets associated with the onset of pathology.
- Citations
- 25
- FWCI
- 7.35
- Field percentile
- top 2%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Altered CD8+ T cell associated aging gene signature in the peripheral blood of patients with Alzheimer's disease.
J. J. Young, H.-J. Park, … I. Kang·bioRxiv·Sep 29, 2022
- Early beta-amyloid accumulation in the brain is associated with peripheral T cell alterations
C. Gericke, T. Kirabali, … A. Gietl·bioRxiv·Jan 17, 2023
- Age-related memory CD8 T cells induce and track Alzheimers-like neurodegeneration
Akanksha Panwar, Altan Rentsendorj, … Christopher J. Wheeler·Proceedings of the National Academy of SciencesPeer-reviewed·Jul 12, 2024
- Peripheral T-cell co-signalling states mark vulnerability and resilience to cerebral Aβ pathology
Anna Mallone, Dario Bachmann, … Christoph Gericke·bioRxiv·Aug 7, 2026
- CAR T cell targeting of inflammatory myeloid progenitors in the bone marrow remodels border-associated macrophages and reverses cognitive aging
Alexander S. Harris, James A. Rouse, … Corina Amor·bioRxiv·Sep 28, 2026
- Single-cell multiomic analysis reveals the involvement of Type I interferon-responsive CD8+ T cells in amyloid beta-associated memory loss
N. Fernando, J. Gopalakrishnan, … H.-Y. Shih·bioRxiv·Mar 18, 2023